Abstract
A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control. However, there is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial is the first large-scale investigator-initiated multicenter study with a prospective, randomized, open, blinded endpoint evaluation (PROBE) design to directly compare cardiovascular mortality and morbidity, incidence of adverse drug reaction, and degree of blood pressure reduction in Japanese hypertensive patients for a combination of angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a calcium antagonist, benidipine hydrochloride, with a response-dependent dose titration scheme. The COPE trial is being conducted with the cooperation of more than 100 centers and clinics in Japan and involves 3,000 patients, who will be followed for 3 years. Eligible patients are being enrolled from May 2003 until May 2006. Results from the COPE trial should provide new evidence for selecting optimal combination therapies for hypertensive patients.
Similar content being viewed by others
Article PDF
References
Kannel WB : Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571–1576.
Gorelick PB, Sacco RL, Smith DB, et al: Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999; 281: 1112–1120.
Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.
Staessen JA, Wang JG, Thijs L : Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.
Turnbull F : Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.
Yamori Y, Nara Y, Mizushima S, Sawamura M, Horie R : Nutritional factors for stroke and major cardiovascular diseases: international epidemiological comparison of dietary prevention. Health Rep 1994; 6: 22–27.
Levi F, Lucchini F, Negri E, La Vecchia C : Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002; 88: 119–124.
Ueshima H, Zhang XH, Choudhury SR : Epidemiology of hypertension in China and Japan. J Hum Hypertens 2000; 14: 765–769.
Koshy S, Bakris GL : Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000; 14: 295–301.
European Society of Hypertension-European Society of Cardiology Guidelines Committee : 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Whitworth JA, World Health Organization, International Society of Hypertension Writing Group : 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension : Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613–634.
Gong L, Zhang W, Zhu Y, et al: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237–1245.
National Intervention Cooperative Study in Elderly Hypertensives Study Group : Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–1133.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717–725.
Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension : Guidelines for the Management of Hypertension 2004. Tokyo, Life Science Publishing Co., Ltd., 2004, pp 4–6.
Hozawa A, Ohkubo T, Kikuya M, et al: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res 2002; 25: 57–63.
Law MR, Wald NJ, Morris JK, Jordan RE : Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H : Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines. Hypertens Res 2002; 25: 175–178.
Saruta T : Current status of calcium antagonists in Japan. Am J Cardiol 1998; 82: 32R–34R.
Hansson L, Hedner T, Dahlof B : Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1: 113–119.
Kalke S, Shah BV, Nair KG, Gala D, Sood OP, Bagati A : Clinical trial of benidipine in mild to moderate hypertension. J Assoc Physicians India 1999; 47: 195–197.
Hoshide S, Kario K, Mitsuhashi T, Ikeda U, Shimada K : Is there any difference between intermediate-acting and long-acting calcium antagonists in diurnal blood pressure and autonomic nervous activity in hypertensive coronary artery disease patients? Hypertens Res 2000; 23: 7–14.
Nomura M, Nakaya Y, Uemura E, et al: Effects of benidipine hydrochloride on autonomic nervous activity in hypertensive patients with high- and low-salt diets. Arzneimittelforschung 2003; 53: 314–320.
Study Group on Long-Term Antihypertensive Therapy : A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension—the GLANT Study. Hypertens Res 1995; 18: 235–244.
Pocock SJ, Simon R : Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103–115.
Ogihara T, Morimoto S, Okaishi K, et al: Questionnaire survey on the Japanese guidelines for treatment of hypertension in the elderly: 1999 revised version. Hypertens Res 2002; 25: 69–75.
Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
Angeli F, Verdecchia P, Reboldi GP, et al: Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens 2004; 17: 817–822.
Yao K, Sato H, Sonoda R, Ina Y, Suzuki K, Ohno T : Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. Hypertens Res 2003; 26: 569–576.
Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S : Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats. Hypertens Res 2003; 26: 635–641.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Ogihara, T., Matsuzaki, M., Matsuoka, H. et al. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial: Rationale and Design. Hypertens Res 28, 331–338 (2005). https://doi.org/10.1291/hypres.28.331
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.28.331
Keywords
This article is cited by
-
Synthesis and vasodilator activity of new 1,4-dihyropyridines bearing sulfonylurea, urea and thiourea moieties
Chemical Papers (2020)
-
Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial
Hypertension Research (2017)
-
Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial
Hypertension Research (2016)
-
Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial
Hypertension Research (2013)
-
Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice
Hypertension Research (2012)
